191 related articles for article (PubMed ID: 24670088)
1. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis.
Chen CL; Chen NC; Hsu CY; Chou KJ; Lee PT; Fang HC; Renn JH
J Clin Endocrinol Metab; 2014 Jul; 99(7):2426-32. PubMed ID: 24670088
[TBL] [Abstract][Full Text] [Related]
2. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis.
Torregrosa JV; Moreno A; Mas M; Ybarra J; Fuster D
Kidney Int Suppl; 2003 Jun; (85):S88-90. PubMed ID: 12753274
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
Huraib S; Abu-Aisha H; Abed J; Al Wakeel J; Al Desouki M; Memon N
Am J Nephrol; 1997; 17(2):118-23. PubMed ID: 9096441
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
7. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
8. Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial.
Wang AY; Tang TK; Yau YY; Lo WK
Am J Kidney Dis; 2024 Apr; 83(4):456-466.e1. PubMed ID: 38040277
[TBL] [Abstract][Full Text] [Related]
9. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
10. [Vitamin D receptor gene polymorphism and the rate of bone loss of the femur neck and lumbar spine in hemodialized patients with chronic renal failure].
Karkoszka H; Chudek J; Strzelczyk P; Wiecek A; Schmidt-Gayk H; Ritz E; Kokot F
Pol Merkur Lekarski; 1998 Oct; 5(28):199-202. PubMed ID: 10101442
[TBL] [Abstract][Full Text] [Related]
11. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
Haghverdi F; Farbodara T; Mortaji S; Soltani P; Saidi N
Iran J Kidney Dis; 2014 Nov; 8(6):461-6. PubMed ID: 25362221
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
13. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
[TBL] [Abstract][Full Text] [Related]
14. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
15. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study.
Chen CL; Chen NC; Wu FZ; Wu MT
Osteoporos Int; 2020 Aug; 31(8):1507-1516. PubMed ID: 32246167
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
17. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
18. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.
Lien YH; Silva AL; Whittman D
Nephrol Dial Transplant; 2005 Jun; 20(6):1232-7. PubMed ID: 15840675
[TBL] [Abstract][Full Text] [Related]
19. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
